

GRIFOLS, S.A.

AUDIT COMMITTEE

REPORT ON RELATED PARTY TRANSACTIONS 2021

The Audit Committee of Grifols, S.A. (the "**Company**") has prepared this annual report on related party transactions (the "**Report**"), in accordance with the Good Governance Code of Listed Companies. It includes the Company's related party transactions carried out between 1 January and 31 December of 2021.

On 18 February 2015 the Board of the CNMV approved the Good Governance Code of Listed Companies, which has been updated in June 2020. The recommendation 6 sets out that:

"Listed companies drawing up the following reports on a voluntary or compulsory basis should publish them on their website well in advance of the annual general shareholders' meeting, even if their distribution is not mandatory:

- a) *Report on auditor independence.*
- b) *Reports of the operation of the audit committee and the nomination and remuneration committee.*
- c) *Audit committee report on related party transactions."*

Pursuant to said recommendation, this Report shall be published on the Company's website well in advance of the Company's 2022 Ordinary General Shareholders' Meeting. Also, the information detailed in this Report is available to the shareholders of the Company in the Company's annual accounts and in its annual corporate governance report for financial year 2021.

During the fiscal year 2021, the main transactions carried out by the Company with other companies of the Group have been the following:

Corporate name of the group' subsidiary	Brief description of the transaction	Amount (in thousands of euros)
Fundación Privada Victor Grifols Lucas	Management or collaboration agreements	400
Probitas Fundación Privada	Management or collaboration agreements	3,563
Access Biologicals LLC	Sales	11,517
Access Biologicals LLC	Purchases	613

Access Biologicals LLC	Operating expenses	2,788
Access Biologicals LLC	Dividends	5,745
Shanghai Raas Blood Products Co. Ltd.	Dividends. The amount is the net result of dividends received and paid to such company. In this sense, the amount is negative.	-3,108
Shanghai Raas Blood Products Co. Ltd.	Financial income	2
Shanghai Raas Blood Products Co. Ltd.	Sales	203,264
Grifols Egypt for Plasma Derivatives (S.A.E.)	Sales	6,027
Mecwins, S.A.	Operating expenses	79

In accordance with the applicable law, the transactions considered significant as a result of its amount or nature, which have been carried out between the Company, or a subsidiary, with other related parties which are considered related parties pursuant to the international accounting standards adopted by the EU, are detailed below:

Company name of the related party	Brief description of the transaction	Amount (in thousands of euros)
Scranton Enterprises, B.V.	These are payments for right-of-use assets between Centuri3n Real Estate S.A.U. and Grifols, S.A., where Scranton Enterprises B.V. (a significant shareholder of Grifols, S.A.) is the sole shareholder of Centuri3n Real Estate S.A.U.	5,332
Scranton Enterprises, B.V.	This consists of sales revenue from the execution of a delegated construction contract between Grifols, S.A. and Centuri3n Real Estate S.A.U., where Scranton Enterprises B.V. (a significant shareholder of Grifols, S.A.) is the sole	7,326

	shareholder of Centuri3n Real Estate S.A.U.	
--	---	--

Barcelona, 24 February 2022
Audit Committee